Related Experiment Video
Updated: Jun 8, 2025

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Identification of cell wall binding domains and repeats in Streptococcus pneumoniae phage endolysins: A molecular and
Tahsin Khan1, Shakhinur Islam Mondal1, Araf Mahmud1
1Department of Genetic Engineering and Biotechnology, Shahjalal University of Science and Technology, Sylhet, Bangladesh.
Abstract:
Streptococcus pneumoniae (pneumococcus) is a multidrug-resistant pathogen associated with pneumonia, otitis media, meningitis and other severe complications that are currently a global threat to human health. The World Health Organization listed Pneumococcus as the fourth of twelve globally prioritized pathogens. Identifying alternatives to antibiotic therapies is urgently needed to combat Pneumococcus. Bacteriophage-derived endolysins can be used as alternative therapeutics due to their bacterial cell wall hydrolyzing capability. In this study, S. pneumoniae phage genomes were screened to create a database of endolysins for molecular modelling and diversity analysis of these lytic proteins. A total of 89 lytic proteins were curated from 81 phage genomes and categorized into eight groups corresponding to their different enzymatically active (EAD) domains and cell wall binding (CBDs) domains. We then constructed three-dimensional structures that provided insights into these endolysins. Group I, II, III, V, and VI endolysins showed conserved catalytic and ion-binding residues similar to existing endolysins available in the Protein Data Bank. While performing structural and sequence analysis with template lysin, an additional cell wall binding repeat was observed in Group II lysin, which was not previously known. Molecular docking performed with choline confirmed the existence of this additional repeat. Group III endolysins showed 99.16 % similarity to LysME-EF1, a lysin derived from Enterococcus faecalis. Furthermore, the comparative computational analysis revealed the existence of CBDs in Group III lysin. This study provides the first insight into the molecular and diversity analysis of S. pneumoniae phage endolysins that could be valuable for developing novel lysin-based therapeutics.
Insights
Multidrug-resistant Streptococcus pneumoniae requires new treatments. This study analyzes pneumococcal phage endolysins, identifying novel therapeutic targets for combating this global health threat.
Area of Science:
- Microbiology and Virology
- Structural Biology
- Drug Discovery
Background:
- Streptococcus pneumoniae (pneumococcus) is a multidrug-resistant pathogen causing severe diseases like pneumonia and meningitis.
- The World Health Organization prioritizes pneumococcus as a global health threat, necessitating urgent development of alternative therapies to antibiotics.
- Bacteriophage-derived endolysins offer potential as antimicrobial agents due to their ability to degrade bacterial cell walls.
Purpose of the Study:
- To screen Streptococcus pneumoniae phage genomes for endolysins.
- To create a database of these endolysins for molecular modeling and diversity analysis.
- To gain insights into the structural and functional characteristics of pneumococcal phage endolysins for potential therapeutic development.
Main Methods:
- Screening of Streptococcus pneumoniae phage genomes to curate endolysins.
- Categorization of 89 endolysins into eight groups based on enzymatically active (EAD) and cell wall binding domains (CBDs).
- Construction of three-dimensional structures, sequence analysis, and molecular docking studies (with choline).
Main Results:
- A database of 89 endolysins from 81 phage genomes was established and categorized.
- Structural analysis revealed conserved catalytic and ion-binding residues in several endolysin groups.
- A novel, previously unknown cell wall binding repeat was identified in Group II endolysins, confirmed by molecular docking.
Conclusions:
- This study provides the first comprehensive molecular and diversity analysis of Streptococcus pneumoniae phage endolysins.
- The identified endolysins, particularly Group II with its additional binding repeat, represent promising candidates for novel lysin-based therapeutics.
- Findings support the potential of bacteriophage endolysins as a viable alternative strategy against multidrug-resistant pneumococcal infections.
Related Concept Videos
Archaeal Cell Wall
Outer Layers of the Cell Envelope
Bacterial Cell Wall
Viral Replication: Lytic Cycle
Formation of Lipopolysaccharides
Lytic Cycle of Bacteriophages

